NCT05254743 2026-04-20
BRUIN-CLL-314
Eli Lilly and Company
Phase 3 Recruiting
Clinical Trials
21 trialsNCT01804686 2026-04-13
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT01886872 2026-04-13
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03462719 2026-04-13
GLOW
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03701282 2026-04-13
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03737981 2026-04-13
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06136559 2026-04-13
BELLWAVE-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT02477696 2026-03-27
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 3 Active not recruiting
NCT02048813 2025-11-28
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03734016 2025-03-30
ALPINE
BeiGene
Phase 3 Completed
NCT02863718 2024-12-30
CLL12
German CLL Study Group
Phase 3 Completed
NCT02950051 2024-12-30
GAIA
German CLL Study Group
Phase 3 Completed
NCT01724346 2024-09-19
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Pharmacyclics LLC.
Phase 3 Completed
NCT02301156 2022-05-20
GENUINE
TG Therapeutics, Inc.
Phase 3 Completed
NCT02264574 2020-09-21
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Pharmacyclics LLC.
Phase 3 Completed
NCT01611090 2020-03-03
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01578707 2019-12-18
RESONATEâ„¢
Pharmacyclics LLC.
Phase 3 Completed
NCT01973387 2018-07-24
A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT02991638 2018-04-12
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
The University of Hong Kong
Phase 3 Unknown
NCT01722487 2017-11-30
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
Pharmacyclics LLC.
Phase 3 Completed
NCT02757040 2016-04-29
Combination of Ibrutinib and As2O3 in the Treatment of CLL
Peking University People's Hospital
Phase 3 Unknown